Home » Abbott Bests Biogen With $27-a-Share Bid for Facet Biotech
Abbott Bests Biogen With $27-a-Share Bid for Facet Biotech
Abbott Laboratories, maker of the arthritis medicine Humira, succeeded in
its bid for Facet Biotech Corp. by offering 54 percent more than Biogen Idec Inc. in its rejected takeover effort.
Bloomberg
Bloomberg
Upcoming Events
-
07May
-
14May
-
30May